Form 4: Day One Biopharmaceuticals Executive Sells 30,000 Shares

Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, sold 30,000 shares of common stock at an average price of $14.2225.

Summary

• Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, filed a Form 4 indicating changes in beneficial ownership.
• On September 10, 2024, Blackman sold 30,000 shares of Day One Biopharmaceuticals' common stock.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 10, 2023.
• The shares were sold at prices ranging from $14.02 to $14.37, with a weighted average price of $14.2225.
• Following the transaction, Blackman directly owns 1,097,535 shares of common stock.
• Blackman also indirectly owns 1,000,000 shares through the 2021 Blackman Family LLC, but disclaims beneficial ownership except to the extent of his and his wife's pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to an executive's stock sale. It doesn't inherently convey positive or negative sentiment, as it's a routine transaction.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies and are often related to personal financial planning. The use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on insider information at the time of the sale.

Comparison to Industry Standards

• Executive compensation and stock ownership are typical for pharmaceutical companies of Day One Biopharmaceuticals' size.
• Comparing Blackman's stock ownership to other executives in similar roles at comparable companies (e.g., Relay Therapeutics, Black Diamond Therapeutics) would provide further context.
• The use of Rule 10b5-1 trading plans is a standard practice among corporate executives to avoid accusations of insider trading.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders if it creates downward pressure on the stock price, although the volume is relatively small compared to the total outstanding shares.
• The sale does not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates